Cross-institution positioning
Aug 6, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchPBLS Institutional Ownership
Parabilis Medicines, Inc.
Latest stored close $28.82 as of Oct 7, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
59/100
1 tracked · 0 comparable
Latest filing
Aug 6, 2026
Positive breadth
1 positive · 0 negative
Recent close
$28.82
Research confidence
Limited
Institutional Research 56/100 · 0 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing Aug 6, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported1
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 59/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 0 reducing/exited.
- Recent insider purchase activity confirms the institutional direction.
Institutional
56/100
Insiders
85/100
Fundamentals
49/100
Events
50/100
Insider filing activity
Aug 22, 2026Over the last 90 days, SEC-coded non-derivative P/S activity includes 14 purchases by 15 reporting owners and 0 sales by 0 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Sep 15, 20264 non-amendment material events in the last 90 days; Latest classified evidence: Regulation FD disclosure. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 13, 2026Net income -50.7% YoY; Free cash flow +17.6% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 66% through its reported 52-week range.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Initial Schedule 13G from Fidelity / FMR.
Filed Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
Aug 6, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Fidelity / FMR
Filed Aug 6, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Fidelity / FMR
Filed Aug 6, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales00 reporting owner(s)
90-day purchase breadth15Multi-insider
90-day sale breadth0
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Aug 22, 2026 | Tendler Craig | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Aug 25, 2026 |
| Jul 22, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 47.3K | $29.77 | Indirect | Jul 22, 2026 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 37.7K | $30.00 | Indirect | Jul 22, 2026 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 6.5K | $29.17 | Indirect | Jul 22, 2026 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 21.7K | $27.96 | Indirect | Jul 22, 2026 |
| Jul 20, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 33.0K | $27.72 | Indirect | Jul 22, 2026 |
| Jul 20, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 98.4K | $27.13 | Indirect | Jul 22, 2026 |
| Jun 15, 2026 | SEBULSKY ALAN | POpen-market or private purchase | Common Stock | 4.1K | $27.10 | Indirect | Jun 16, 2026 |
| Jun 15, 2026 | SEBULSKY ALAN | POpen-market or private purchase | Common Stock | 5.0K | $26.00 | Indirect | Jun 16, 2026 |
| Jun 12, 2026 | SEBULSKY ALAN | POpen-market or private purchase | Common Stock | 8.4K | $27.67 | Indirect | Jun 16, 2026 |
| Jun 11, 2026 | Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC | CConversion of derivative · derivative | Series F Preferred Stock | 527.1K | $0.00 | Indirect | Jun 29, 2026 |
| Jun 11, 2026 | Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC | CConversion of derivative | Common Stock, par value $0.0001 per share | 527.1K | $9.48 | Indirect | Jun 29, 2026 |
| Jun 11, 2026 | Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC | POpen-market or private purchase | Common Stock, par value $0.0001 per share | 125.0K | $20.00 | Indirect | Jun 29, 2026 |
| Jun 11, 2026 | Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC | POpen-market or private purchase | Common Stock, par value $0.0001 per share | 375.0K | $20.00 | Indirect | Jun 29, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | CConversion of derivative · derivative | Series F Preferred Stock | 1.7M | — | Indirect | Jun 15, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | CConversion of derivative · derivative | Series F Preferred Stock | 9.4M | — | Indirect | Jun 15, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | CConversion of derivative · derivative | Series E Preferred Stock | 160.6K | — | Indirect | Jun 15, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | CConversion of derivative · derivative | Series E Preferred Stock | 642.3K | — | Indirect | Jun 15, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 1.5M | $20.00 | Indirect | Jun 15, 2026 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Voting Common Stock | 19.7M | $20.00 | Indirect | Jun 15, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events1
90-day capital-related0
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 15, 2026 | 8-K | 7.01 | Regulation FD disclosure | — | Filing |
| Sep 2, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Aug 25, 2026 | 8-K | 5.02, 7.01, 9.01 | Director or executive change; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 13, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jun 11, 2026 | 8-K | 1.01, 3.02, 5.03, 9.01 | Material definitive agreement; Unregistered sale of equity securities; Charter or bylaw change; Financial statements / exhibits | Equity | Filing |
| Jun 10, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Jun 10, 2026 | 424B4 | — | Prospectus filing | Capital-related | Filing |
| Jun 9, 2026 | S-1/AAmendment | — | Securities registration statement | Capital-related | Filing |
| Jun 4, 2026 | S-1/AAmendment | — | Securities registration statement | Capital-related | Filing |
| May 27, 2026 | S-1/AAmendment | — | Securities registration statement | Capital-related | Filing |
| May 19, 2026 | S-1 | — | Securities registration statement | Capital-related | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Revenue
$148.0K
Q2 2026
10-Q filed Aug 13, 2026
Operating income
$-50.9M
Q2 2026
-39.3% YoY 10-Q filed Aug 13, 2026
Operating margin
-34,382.4%
Q2 2026
10-Q filed Aug 13, 2026
Net income
$-52.5M
Q2 2026
-50.7% YoY 10-Q filed Aug 13, 2026
Diluted EPS
$-2.32
Q2 2026
+89.6% YoY 10-Q filed Aug 13, 2026
Operating cash flow
$-52.8M
YTD through Jun 30, 2026
+19.0% YoY 10-Q filed Aug 13, 2026
Free cash flow
$-53.8M
YTD through Jun 30, 2026
+17.6% YoY 10-Q filed Aug 13, 2026
Cash & equivalents
$1.1B
As of Jun 30, 2026
+1,252.2% YoY 10-Q filed Aug 13, 2026
Long-term debt
$6.4M
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Assets
$1.2B
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Liabilities
$127.5M
As of Jun 30, 2026
10-Q filed Aug 13, 2026
Stockholders’ equity
$1.0B
As of Jun 30, 2026
+330.1% YoY 10-Q filed Aug 13, 2026
View recent revenue trend
Quarterly
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $148.0K | — |
| Ended Jun 30, 2025 | $0 | — |
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$35.72
View live quote ↗
52-week low
$24.51
Jun 15, 2026
52-week high
$41.49
Aug 20, 2026
Below 52-week high
13.9%
1W return
-10.2%
1M return
-3.6%
3M return
+42.8%
6M return
YTD return
1Y return
30-day volatility
46.4%
90-day volatility
63.8%
1Y max drawdown
-20.9%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 2 of 2 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 quarter end Aug 13, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 10.3M | $28.82 | |||
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Initial Schedule 13G | Initial Schedule 13G | 10.3M | 8.50% | $27.37 | $35.58 | $28.82 |
Explore more institutional activity
Related research
Compare PBLS with other securities showing similar institutional activity or recent accumulation across several tracked institutions.